Trial Profile
Effects of niacin versus ezetimibe on serum paraoxygenase and arylesterase activities of HDL cholesterol in patients with or at risk for CAD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2012
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; HMG-CoA reductase inhibitors; Niacin
- Indications Coronary artery disease
- Focus Pharmacodynamics
- 07 Apr 2012 New trial record
- 27 Mar 2012 Results presented at the 61st Annual Scientific Session of the American College of Cardiology.